Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
Semaglutide (Generic)
| Semaglutide-A (Generic) Semaglutide | ||||||
|
Shipped from Canada | ||||||
| | ||||||
| Select product strength & quantity:
Who is the product for? YouOtherAdd Family Member/PetYou must be logged in to add additional members to the order. Don't have an account? or Add Family Member/PetSign inTo continue, please enter your email address and password that you use for your account. | ||||||
General Medication Fact Sheet for Semaglutide
| Field | Information |
|---|---|
| Generic Name | Semaglutide |
| Brand Name Versions | Ozempic, Wegovy, Rybelsus |
| Purpose | Management of Type 2 Diabetes; weight management (depending on formulation) |
| Mechanism of Action | GLP-1 receptor agonist that increases insulin secretion, reduces glucagon release, slows gastric emptying, and reduces appetite |
| Dosage Forms | Subcutaneous injection, oral tablet |
| Available Strengths | Injection: 0.25 mg, 0.5 mg, 1 mg, 2 mg Oral: 3 mg, 7 mg, 14 mg |
| Dosage Frequency | Injection: once weekly Oral: once daily |
| Common Side Effects | Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite |
| Serious Side Effects | Pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal reactions, possible thyroid C-cell tumors (boxed warning in some formulations) |
| Drug Interactions | Insulin, sulfonylureas (increased hypoglycemia risk), other GLP-1 agents, medications affected by delayed gastric emptying |
| Important Notes | Dose must be gradually increased to reduce GI side effects. Not for Type 1 diabetes. Monitor blood glucose regularly. |
| Storage | Refrigerate injection pens; protect from light. Oral tablets stored at room temperature. |
| Missed Dose | Injection: take within 5 days if missed; otherwise skip. Oral: take next scheduled dose |
| Alternatives | Liraglutide, Dulaglutide, Tirzepatide, Metformin |
Semaglutide Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Liraglutide | GLP-1 receptor agonist | Daily injection; older GLP-1 option |
| Dulaglutide | GLP-1 receptor agonist | Once-weekly injection |
| Tirzepatide | GIP/GLP-1 receptor agonist | Newer agent with stronger weight-loss effects |
| Metformin | Reduces hepatic glucose production | First-line for Type 2 diabetes; oral only |
Semaglutide Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Nausea | Pancreatitis |
| Vomiting | Gallbladder disease |
| Diarrhea | Acute kidney injury |
| Constipation | Severe dehydration |
| Abdominal discomfort | Possible thyroid C-cell tumors (boxed warning) |
| Loss of appetite | Severe allergic reactions |
Semaglutide Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Type 2 Diabetes (Injection) | 0.25 mg once weekly for 4 weeks | 0.5–1 mg weekly (may increase up to 2 mg) | Inject subcutaneously in abdomen, thigh, or upper arm |
| Weight Management | 0.25 mg once weekly for 4 weeks | Gradual increase up to 2.4 mg weekly | Dose escalation every 4 weeks to reduce GI effects |
| Oral Form (Type 2 Diabetes) | 3 mg once daily for 30 days | 7–14 mg once daily | Take on empty stomach with water only |
